Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh(Sheba Medical Center), Andrew Tutt(Institute of Cancer Research), Mark Wickens(AstraZeneca (United Kingdom)), Ursula A. Matulonis(Dana-Farber Cancer Institute), Ana Oaknin(Hebron University), Katherine M. Bell‐McGuinn(Memorial Sloan Kettering Cancer Center), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), Richard T. Penson(Massachusetts General Hospital), Niklas Loman(Lund University), James Carmichael(AstraZeneca (United Kingdom)), Rita K. Schmutzler(The University of Melbourne), Michael Friedländer(Prince of Wales Hospital), Bethan Powell(University of California, San Francisco), Jeffrey N. Weitzel(Cancer Genetics (United States))
Cited by 2,292
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k